期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 93, 期 5, 页码 402-408出版社
WILEY
DOI: 10.1038/clpt.2013.2
关键词
-
资金
- National Institutes of Health (NIH)
- NIH/National Institute of General Medical Sciences (NIGMS) Pharmacogenomics Research Network [U01 GM92666, U01 HL105198]
- ALSAC
- NIH/NIGMS [R24 GM61374]
- Agency for Healthcare Research and Quality [R01 HS19818-01]
- NIMH [R01 MH082784]
- Canadian Institutes of Health Research
- Ontario Mental Health Foundation
- Ministry of Research and Innovation of Ontario
- [R01 GM63674]
- [R01 DA14211]
- [R01 GM088076]
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites. Evidence from published literature is presented for CYP2D6 and CYP2C19 genotype-directed dosing of tricyclic antidepressants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据